Plumbing the Core and Nibbling at the Margins of Cancer

Cancer Commons Editor in Chief George Lundberg, MD, is the face and curator of this invitation-only column

  • August 21, 2020  

    The Power of Precision Medicine is Exemplified by Tempus

    With: Nike Beaubier, MDNamratha Sastry, PhD

    Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.

  • June 30, 2020  

    Helping Cancer Patients Access their Own Health Data

    With: Deven McGraw

    For many cancer patients, the ability to access one’s own medical records can aid their treatment decisions, or allow them to donate their personal data for research that could help other patients. But these records can be difficult to obtain and sort through. Here, our Curious Dr. George asks Deven McGraw, Chief Regulatory Officer at Ciitizen, how her company helps patients access and organize… Read more »

  • June 10, 2020  

    How I Cope with the Tsunami of Cancer and COVID-19 Info

    With: Kevin Knopf, MD

    Oncologists worldwide face the challenge of staying on top of the latest treatments, research findings, and other information that could help them treat their patients more effectively. Now, they must do so in the context of COVID-19. Here, our Curious Dr. George asks Kevin Knopf, MD, MPH, Division Chief of Hematology/Oncology at Highland Hospital/Alameda Health Systems in Oakland, California, how he keeps up. Dr.… Read more »

  • May 20, 2020  

    How the Coronavirus Pandemic Impacts Cancer Care: Our Survey Results

    With: Lola Rahib, PhD

    The ongoing COVID-19 pandemic presents unprecedented challenges to cancer patients. Many have experienced changes to their care, and some face increased risk of infection or worse prognosis if they are infected. In partnership with the company xCures, Cancer Commons is studying how COVID-19 impacts cancer patients. Here, our Curious Dr. George asks Cancer Commons Director of Scientific and Clinical Affairs Lola Rahib, PhD, about… Read more »

  • April 27, 2020  

    The Challenges of Using Artificial Intelligence to Improve Cancer Treatment

    With: Jeff Shrager, PhDRazelle Kurzrock, MD

    In a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile. Here, AI expert Jeff Shrager, PhD, responds, and Kurzrock offers a rebuttal. Shrager is Co-Founder and Director of Research at xCures, and was formerly Director of Research at Cancer Commons. He is also an… Read more »

  • April 3, 2020  

    How to Beat COVID-19 with Real-Time, Real-World Data

    With: Mark Shapiro, PhD

    As the COVID-19 pandemic continues, researchers around the world are working quickly to develop strategies to treat and prevent this disease. In partnership with the company xCures, Cancer Commons is studying how COVID-19 impacts cancer patients. Meanwhile, xCures has launched larger initiative, BEAT19, to gather information from everyone and anyone who wishes to participate—whether they’ve had cancer, COVID-19, or neither. Here, our Curious Dr.… Read more »

  • March 9, 2020  

    Facilitating Access to Treatment for Children with Brain Cancer

    With: Leslie Jared, RN, MSN

    A Q&A with Leslie Jared, RN, MSN, Nurse Navigator at Cancer Commons. Email: leslie.jared@cancercommons.org Q: A midline glioma is a type of brain tumor that is particularly dangerous because of its nature and its location in the brain. It often afflicts children. An investigational drug called ONC201 has shown early promise in some patients whose tumors have a specific genetic mutation called H3 K27M.… Read more »

  • March 2, 2020  

    Using Artificial Intelligence to Match Combination Targeted Therapies in Oncology

    With: Razelle Kurzrock, MD

    A Q&A with Razelle Kurzrock, MD, Director of the Center for Personalized Cancer Therapy and the Rare Tumor Clinic at U.C. San Diego, and Co-Founder and Board Member of CureMatch, Inc. Email: razelle@curematch.com Q: The new understanding of many cancers brought about by molecular testing has led to a whole new field: precision oncology, which emphasizes targeted and immunotherapy. While promising, and sometimes spectacularly… Read more »

  • February 21, 2020  

    Comprehensive Molecular Testing Needed for Stage IV Lung Cancer

    With: David Spigel, MD

    A Q&A with David Spigel, MD, Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. Email: dspigel@tnonc.com Q: You are an expert medical oncologist with particular interest in lung cancer. The various forms of lung cancer are serious diagnoses, all potentially lethal malignancies. There are theoretical, investigational, and clinical justifications to perform molecular testing of… Read more »

  • November 4, 2019  

    Using Molecular Testing to Guide Treatment for Advanced Colorectal Cancer

    With: Kalpana Kannan, PhD

    A Q&A with Kalpana Kannan, PhD, former Scientist at Cancer Commons Q: Colorectal cancer is common, and although many cases in earlier stages are cured by surgery alone or with adjuvant chemotherapy, it is still a lethal threat for many patients. Nonetheless, several new targeted and immunotherapeutic agents are now available. When should patients receive molecular testing for their colorectal cancer, what information should… Read more »